1. Home
  2. NXDT vs PRLD Comparison

NXDT vs PRLD Comparison

Compare NXDT & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NXDT

NexPoint Diversified Real Estate Trust

HOLD

Current Price

$4.88

Market Cap

259.1M

Sector

Finance

ML Signal

HOLD

Logo Prelude Therapeutics Incorporated

PRLD

Prelude Therapeutics Incorporated

SELL

Current Price

$4.35

Market Cap

218.0M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
NXDT
PRLD
Founded
2012
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
259.1M
218.0M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
NXDT
PRLD
Price
$4.88
$4.35
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$5.67
AVG Volume (30 Days)
125.2K
506.5K
Earning Date
01-01-0001
05-13-2026
Dividend Yield
9.66%
N/A
EPS Growth
N/A
23.21
EPS
0.99
N/A
Revenue
N/A
$12,140,000.00
Revenue This Year
N/A
$320.10
Revenue Next Year
N/A
$100.00
P/E Ratio
$4.86
N/A
Revenue Growth
N/A
73.43
52 Week Low
$2.55
$0.75
52 Week High
$5.49
$5.54

Technical Indicators

Market Signals
Indicator
NXDT
PRLD
Relative Strength Index (RSI) 48.20 48.21
Support Level $3.37 $1.09
Resistance Level $4.96 $5.43
Average True Range (ATR) 0.29 0.52
MACD -0.05 -0.09
Stochastic Oscillator 35.39 25.88

Price Performance

Historical Comparison
NXDT
PRLD

About NXDT NexPoint Diversified Real Estate Trust

NexPoint Diversified Real Estate Trust is an externally advised REIT focused on the acquisition, asset management, development, and disposition of opportunistic, value-add investments in real estate properties throughout the United States. The company has two reportable segments: The Diversified reportable segment is focused on investing in various commercial real estate property types and across the capital structure, including but not limited to, equity, mortgage, debt, mezzanine debt and preferred equity. The Hospitality segment is focused on operating and renovating its U.S. located hospitality assets that meet its investment objective and criteria. Its Portfolio includes investments in the single-family rental, self-storage, office, hospitality, life science and multifamily sectors.

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.

Share on Social Networks: